// App-Quantinova.ai

: EFFICACY AND SAFETY OF ABATACEPT IN ACTIVE PRIMARY SJÖGREN’S SYNDROME: RESULTS OF A RANDOMISED PLACEBO-CONTROLLED PHASE III TRIAL

Researchers

Presenter

  • Alan Baer

Principal Investigators

  • Jacques-Eric Gottenberg

  • E. William St. Clair

  • Takayuki Sumida

  • Tsutomu Takeuchi

  • Raphale Seror

  • Gary Foulks

  • Marleen Nys

  • Alyssa Johnsen

  • Robert Wong

  • Neelanjana Ray

  • Hendrika Bootsma

Medical Centers

  • Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, United States of America

  • Strasbourg University, Strasbourg, France

  • Duke University Medical Center - Durham - United States of America

  • University of Tsukuba, Tsukuba, Japan

  • University Hospitals of Paris-Sud Bicêtre, Paris, France

  • University of Louisville School of Medicine, Louisville, United States of America

  • Bristol-Myers Squibb, Braine-lAlleud, Belgium

  • Bristol-Myers Squibb Company, Lawrencville, NJ, United States of America

  • University of Groningen and University Medical Center Groningen, Groningen, Netherlands

Locations

  • France

  • Japan

  • Belgium

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • Hydroxychloroquine

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved